Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Cochlear (ASX:COH) Brings Medical Device Background to Board With Ian Meredith

Cochlear said Meredith will join as an independent non-executive board member from 1 December. He is described as a globally recognised cardiologist bringing more than 30 years of medical background to the board. His background covers serving as global chief medical officer at Boston …

Aditi Sarkar | 19 September 2026

Racura Oncology (ASX:RAC): Bisantrene Research Remains Central to Cancer Drug Development Strategy

Racura Oncology Ltd (ASX:RAC) is a clinical-stage healthcare company developing cancer therapies based around bisantrene. Formerly known as Race Oncology, the company has continued development of RC220, a reformulated version of bisantrene designed for targeted oncology applications. This article reviews the company’s research strategy, …

Sonal Goyal | 19 September 2026

Terragen Holdings (ASX:TGH): Microbial Technology Shapes Agricultural Biotechnology Strategy

Terragen Holdings Limited (ASX:TGH) is an Australian agricultural biotechnology company developing microbial-based products designed to support animal and soil health. The company focuses on biological solutions that use beneficial microbes as alternatives within agricultural systems. This article examines Terragen’s technology platform, product portfolio and …

Sonal Goyal | 19 September 2026

Oakridge International (ASX:OAK): Nurse Call Technology Supports Healthcare Systems Strategy

Oakridge International Ltd (ASX:OAK) is an Australian healthcare technology company focused on nurse call systems and related communication solutions. Through its JCT Healthcare subsidiary, the company develops and distributes technology used across hospitals, aged care facilities, disability care and supported living environments. This article …

Sonal Goyal | 18 September 2026

Acrux (ASX:ACR): Women’s Health Strategy Adds a New Dimension to Pharmaceutical Development

Acrux Limited (ASX:ACR) is a Melbourne-based specialty pharmaceutical company focused on developing topical and transdermal medicines. The company combines a commercial genericsBusinesswith research programmes targeting additional healthcare opportunities, including a female testosterone product. This article reviews Acrux’s operating model, development activities and the factors …

Sonal Goyal | 18 September 2026

The Calmer Co (ASX:CCO): Kava Beverage Strategy Drives Consumer Wellness Expansion

The Calmer Co International Limited (ASX:CCO) is a consumer wellness company focused on kava-based beverages and botanical products. The company markets products including FZZR sparkling kava beverages along with FijiKava and Taki Mai brands. This article examines how the company is developing a consumer …

Sonal Goyal | 18 September 2026

Amplia Therapeutics (ASX:ATX): Cancer Trial Data Drives Narmafotinib Development Path

Amplia Therapeutics Ltd (ASX:ATX) is a Melbourne-based clinical-stage biotechnology company focused on developing targeted cancer therapies. Its lead programme, narmafotinib, is being evaluated for pancreatic cancer through clinical studies. This article examines the role of trial data and the company’s pathway towards further development.

Sonal Goyal | 18 September 2026

Clinuvel Pharmaceuticals (ASX:CUV): Rare Disease Medicine Supports Global Growth Strategy

Clinuvel Pharmaceuticals Limited (ASX:CUV) is an Australian biotechnology company focused on developing treatments for rare diseases and specialised medical conditions. Its lead product, SCENESSE (afamelanotide), is approved for erythropoietic protoporphyria (EPP), a rare inherited disorder affecting sunlight tolerance. This article examines the company’s commercial …

Sonal Goyal | 18 September 2026

CSL (ASX:CSL): Rare Disease Medicines Remain Central to Global Healthcare Strategy

CSL Limited (ASX:CSL) is an Australian healthcare company focused on developing andManufacturingplasma-derived therapies, vaccines and specialty medicines. The company serves patients with rare and serious medical conditions through businesses including CSL Behring, CSL Vifor and CSL Seqirus. This article examines how rare disease medicines …

Sonal Goyal | 18 September 2026

Aroa Biosurgery (ASX:ARX): Tissue Repair Scaffolds Support Regenerative Medicine Growth

Aroa Biosurgery Limited (ASX:ARX) is a New Zealand-based medical technology company focused on regenerative medicine products for soft-tissue repair. The company develops scaffold technologies designed to support the body’s natural healing processes in areas including wound care, hernia repair and reconstruction. This article examines …

Sonal Goyal | 18 September 2026
Support

Hi! How can we help you today?

Loading…